Powerful Biology, Transformative Impact
Through our seamless, in-house integration of biology and biologics, we are building a robust pipeline of first-in-class and best-in-class drug candidates. Regardless of therapeutic area or disease, our drug candidates each target powerful disease-driving biology with the intent of delivering a transformative impact for patients.
NGM Bio has worldwide commercial rights to NGM282.
Our most advanced program, NGM282 (aldafermin) is an engineered variant of the human hormone fibroblast growth factor 19, or FGF19, which we are developing as a once-daily injection for the treatment of NASH. FGF19 is a highly specific and potent regulator of liver fat metabolism and bile acid synthesis that we believe is responsible for some of the beneficial effects of gastric bypass surgery on NASH.
Preliminary results from Phase 2 clinical trials have provided clinical proof of concept of NGM282 (aldafermin) by demonstrating statistically significant reductions in liver fat, liver transaminases and biomarkers of fibrosis, which has translated to improvements in liver histology and fibrosis at 12 weeks.
Clinical Development Status
We are currently underway with our Phase 2b dose range-finding ALPINE 2/3 study, which will assess the efficacy, safety and tolerability of NGM282 (aldafermin) compared to placebo in patients with biopsy-confirmed NASH and stage F2-F3 liver fibrosis.
FGFR1c/KLB Agonistic Antibody
NASH, Type 2 Diabetes
Merck licensed NGM313 and plans to conduct a Phase 2b study to evaluate the effect of NGM313 on liver histology and glucose control in NASH patients with or without diabetes.
NGM313 is an agonistic antibody binding to fibroblast growth factor receptor 1c-beta-klotho, or FGFR1c/KLB, which regulates insulin sensitivity, blood glucose and liver fat. NGM313, being developed as a once-monthly injection, has the potential to be a best-in-class insulin sensitizer for the treatment of type 2 diabetes (T2D) and NASH. NGM313 works by selectively activating the FGFR1c/KLB co-receptor complex, which regulates energy expenditure and glucose uptake in fat cells and other tissues.
In November 2018, NGM presented preliminary data at AASLD’s The Liver Meeting® in San Francisco from a Phase 1b proof-of-concept clinical trial of NGM313 in obese, insulin resistant subjects with nonalcoholic fatty liver disease, or NAFLD. The data demonstrated that a single dose of NGM313 resulted in a statistically significant reduction in liver fat content and improvements in multiple metabolic parameters.
Program Status and Upcoming Milestone
In January 2019, Merck exercised its option to license NGM313 (now renamed MK-3655). This one-time option to license NGM313, part of the original agreement announced by NGM and Merck in 2015, was triggered by NGM’s completion of the Phase 1b clinical study of NGM313. Based on the findings of this study, Merck intends to advance MK-3655 into a Phase 2b study to evaluate the effect of MK-3655 on liver histology and glucose control in NASH patients with or without diabetes.
GFRAL Antagonistic Antibody
Cancer Anorexia / Cachexia Syndrome
Merck has a one-time option to license NGM120 upon our completion of a proof-of-concept study in humans.
NGM120 is a long-acting antagonistic antibody binding glial cell-derived neurotrophic factor receptor alpha-like, or GFRAL, that is designed to inhibit the effects of elevated GDF15 levels on cancer anorexia/cachexia syndrome, or CACS, and possibly, cancer. NGM120 works by selectively inhibiting the interaction between GDF15 and its cognate receptor GFRAL, through which the autonomic nervous system and, possibly, the neuroendocrine axis influence the body’s fuel flux to propel uncontrolled weight loss associated with many types of cancer and, possibly, cancer itself, in cancer patients who have high serum levels of GDF15.
Clinical Development Status
We have completed a Phase 1 double blind, placebo-controlled single ascending dose and multiple ascending dose study designed to evaluate the safety, tolerability and pharmacokinetics of NGM120 in healthy subjects. Preliminary results demonstrated that NGM120 was well-tolerated at all doses studied and the pharmacokinetics support once-monthly dosing. In late 2019, we plan to initiate a Phase 1a/1b clinical study to further evaluate the safety, tolerability and pharmacokinetics of NGM120, and to gather preliminary evidence of anti-cancer and anti-CACS activity in patients with select solid tumors, including pancreatic cancer.
Merck has a one-time option to license NGM217 upon completion of a proof-of-concept study in humans.
NGM217 is a long-acting antibody binding an undisclosed target, designed to restore pancreatic islet function and increase insulin production in patients with diabetes. NGM217 is in a Phase 1 clinical trial where we are assessing its safety and tolerability profile in adults with diabetes.
Complement C3 Inhibitory Antibody
Dry Age-Related Macular Degeneration
Merck has a one-time option to license NGM621 upon our completion of a proof-of-concept study in humans.
NGM621 is an inhibitory antibody binding complement C3, a key node of all three complement pathways. Human genetics data suggest that inhibition of complement can effectively slow the progression of vision loss in patients with advanced age-related macular degeneration, or AMD. A Phase 1 clinical study is underway to evaluate the safety, tolerability and pharmacokinetics of up to two intravitreal doses of NGM621 in patients with geographic atrophy, an advanced form of dry AMD.
NGM Bio has worldwide commercial rights to NGM395.
NGM395 is an engineered long-acting variant of the human hormone known as growth differentiation factor 15, or GDF15. GDF15 drives profound metabolic activity by regulating fuel flux and has been considered a challenging therapeutic target. NGM discovered that metabolic activity of GDF15 is mediated by glial cell-derived neurotrophic factor receptor alpha-like, or GFRAL, which is located in a region of the brain stem outside of the blood-brain barrier. NGM395 is designed to stimulate a pathway that modulates the autonomic nervous system and, possibly, the neuroendocrine axis to modify body weight and fat levels in the body.
"We are a biology-based company, not a disease-focused company. While we started off in metabolic diseases, we weren't afraid to explore other disease areas and learn from those. The opportunity to go into different diseases really interested me. It just makes it very diverse from the biology standpoint."